BAROnova is a Silicon Valley based venture-backed company that has developed a novel non-surgical solution for obesity. BAROnova’s TransPyloric Shuttle®* (TPS®) is designed to slow gastric emptying which creates longer and more rapid satiety – a proven mechanism for driving significant weight loss. The TPS is placed endoscopically during a simple 15-minute outpatient procedure and is removed in a similar manner. The device resides in patients for up to 12 months to assist in sustained weight-loss.
The world-wide market for this treatment is over 600M people with more than 75M people in the U.S. alone.
BAROnova has recently completed its ENDObesity II Study – a twelve-month multicenter US pivotal trial designed to evaluate the safety and effectiveness of the TransPyloric Shuttle.
*The BAROnova TransPyloric Shuttle is an investigational device and is not available for sale within the United States or internationally. The TransPyloric Shuttle device and methods of use are covered by various US and foreign patents.